Chemical Structure (Rivastigmine 01)
Rivastigmine Tartrate Capsule
Product Images NDC 75834-133
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Rivastigmine Tartrate (NDC 75834-133). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Nivagen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Rivastigmine 02)
Figure 2 (Rivastigmine 03)
The text displays a table showing the cumulative percentage of patients from two treatment groups based on their change in ADAS-cog scores. The first group is taking a placebo, while the second group is taking a medication with 1-4 mg/day or 6-12 mg/day. The top row displays the change in ADAS-cog scores (-7 to 0), and the left column displays the treatment groups' names. The text also shows a chart with a range of change in scores from baseline. The description is explaining the statistical results of an experiment, which is evaluating the effectiveness of the medication on patients with ADAS-cog scores.*
Figure 3 (Rivastigmine 04)
This appears to be a description of a medication or treatment called "Placebo" with dosage information ranging from 1-4mg to 6-12mg and a cost listed as £25 or S20. The other text is not clear but appears to be related to a rating scale called CIBIC - Plus which possibly assesses the effectiveness of the treatment.*
Figure 4 (Rivastigmine 05)
This is a chart or graph showing the mean change in AADAS-cog rating from the baseline over a period of 26 weeks during treatment. It appears to relate to clinical improvement or decline.*
Figure 5 (Rivastigmine 06)
Figure 6 (Rivastigmine 07)
This appears to be a table showing the percentage of patients and their corresponding ratings based on a CIBIC-Plus assessment. The categories include "Markedly improved," "Minimally improved," "Unchanged," "Minimally worse," and "Markedly worse." The different columns appear to relate to different dosages or treatments, with "Placebo," "O1-4mg," and "6-12 mg" listed. However, it is not clear what condition or disease is being assessed, so specific context is needed to understand the significance of the information.*
Figure 7 (Rivastigmine 08)
This is a graph or chart that shows the clinical improvement (labeled as "Exeion Clinical") versus the decline seen in those who took placebo medication. The X-axis measures time in weeks during treatment (up to 24 weeks), while the Y-axis represents the level of clinical improvement or decline. The chart was likely produced as part of a study or trial, but without additional context or information, it is difficult to deduce more specific details.*
Figure 8 (Rivastigmine 09)
This appears to be a graph or chart showing the percentage of patients for a study involving Exelon and a placebo, represented by different levels of improvement or worsening. The chart also includes a marker for ADCS-CGIC racing, although it is unclear what this refers to without further context.*
Principal Display Panel (1.5 mg Capsule Bottle Label)
This is a description of Rivastigmine Tartrate Capsules USP, containing 60 capsules in one package. Each capsule contains Rivastigmine Tartrate USP, equivalent to Rivastigmine 1.5 mg. The usual dosage is indicated on the prescribing information. The medication should be stored at 25°C (77°F), with excursions permitted to 15-30°C (50-86°F) in a tight container. The manufacturer is Nivagen Pharmaceuticals and the product was manufactured by Cadila Pharmaceuticals Ltd. in India. The expiry date appears to be January 2017.*
Principal Display Panel (3 mg Capsule Bottle Label)
This is a medication containing Rivastigmine Tartrate USP with an equivalent to Rivastigmine 3 mg. The usual dosage is specified in the prescribing information. The capsules should be stored at 25°C (77°F) but can be allowed excursions to 15-30°C (50 to 86°F). The capsules are USP Controlled Capsules and should be stored in a tight container at room temperature. This medication is manufactured for Nivagen Pharmaceuticals, Inc. Mig. Lic. No.: G/1500. The manufacturer's address is Cadila Pharmaceuticals Ltd., Dholka, Dist. Ahmedabad, Gujarat State, India. The text also includes information on NDC 75834-134-60 and a toll-free number for Nivagen Pharmaceuticals, Inc.*
Principal Display Panel (4.5 mg Capsule Bottle Label)
This is a description of a medication called Rivastigmine Tartrate in capsule form with 60 capsules included in each container. Each capsule contains 4.5mg of Rivastigmine Tartrate. The usual dosage information is found in the prescribing information for the medication. It is recommended to store the medication at room temperature (25°C/77°F) with excursions permitted to 15-30°C (50 to 86°F). The medication should be dispensed in a light container and was manufactured for Nivagen Pharmaceuticals in Sacramento, CA. The manufacturer of this medication is Cadila Pharmaceuticals Ltd, located in Gujarat State, India.*
Principal Display Panel (6 mg Capsule Bottle Label)
This is a prescription drug with NDC number 75834-136-60 manufactured by Nivagen Pharmaceuticals Inc., Sacramento, CA. The drug comes in capsule form with each capsule containing 6mg Rivastigmine Tartrate USP. It is used for the treatment of dementia associated with Alzheimer's and Parkinson's diseases. The usual dosage is available in the prescribing information, and the drug must be stored in tight containers at a controlled room temperature. It is manufactured by Cadila Pharmaceuticals Ltd. Gujarat State, India. The manufacturing license number is 6/1500. The text was last issued in January 2017.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
